Osprey raises $11M for protein therapeutics
Osprey Pharmaceuticals U.S.A. has raised $11 million in a first round of funding, according to VentureWire. The San Francisco company’s protein therapeutics treatment targets kidney disease. Burrill & Co. led the round, with participation from BDC Venture Capital, GeneChem Therapeutics Venture Fund, Novo Nordisk Biotech Fund, Western Technology Seed Investment Fund and Yasuda Enterprise Development.
Next Story: Pathwork Diagnostics raises $20M for cancer diagnostic tests
Previous Story: Space Pencil raises $800,000 for web analytics
About the Author, Anthony Ha
Anthony is VentureBeat's assistant editor, as well as its reporter on enterprise technology, cloud computing, and tech policy. Before joining VentureBeat in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. You can also follow Anthony on Twitter.